Available treatment options for the management of Lambert-Eaton myasthenic syndrome

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 10, 2006, Pages 1323-1336

  Verschuuren, Jan J G M ^a   Wirtz, Paul W ^a   Titulaer, Maarten J ^a   Willems, Luuk N A ^a   Van Gerven, Joop ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Aminopyridine; Azathioprine; Guanidine; Immunosuppression; Lambert Eaton myasthenic syndrome; Plasmapheresis; Prednisone; Pyridostigmine; Small cell lung cancer

Indexed keywords

4 AMINOPYRIDINE; ANTINEOPLASTIC AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CISPLATIN; ETOPOSIDE; GUANIDINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; POTASSIUM CHANNEL BLOCKING AGENT; PREDNISOLONE; PYRIDOSTIGMINE;

EATON LAMBERT SYNDROME; HUMAN; IMMUNOTHERAPY; LUNG TUMOR; METHODOLOGY; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMALL CELL CARCINOMA;

4-AMINOPYRIDINE; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CHOLINESTERASE INHIBITORS; CISPLATIN; ETOPOSIDE; GUANIDINE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LAMBERT-EATON MYASTHENIC SYNDROME; LUNG NEOPLASMS; PARASYMPATHOMIMETICS; PLASMAPHERESIS; POTASSIUM CHANNEL BLOCKERS; PREDNISOLONE; PYRIDOSTIGMINE BROMIDE; RANDOMIZED CONTROLLED TRIALS;

EID: 34548631186     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.10.1323     Document Type: Review

References (93)

1. ANDERSON H, CHURCHILL-DAVIDSON HD, RICHARDSON AT: Bronchial neoplasm with myasthenia. Lancet (1953) 2:1291. • Probably the first detailed description of a patient with LEMS.
2. HENSON RA, RUSSELL DS, WILKINSON M: Carcinomatous neuropathy and myopathy, a clinical and pathological study. Brain (1954) 77:82.
3. HEATHFIELD KWG, WILLIAMS JRB: Peripheral neuropathy, and myopathy associated with bronchogenic carcinoma. Brain (1954) 77:122.
4. LAMBERT EH, EATON LM, ROOKE ED: Defect of neuromuscular conduction associated with malignant neoplasms. Am. J. Physiol. (1956) 187:612-613. •• The first paper describing the electrophysiological characteristics of the syndrome. The syndrome was named after the authors of this paper.
5. LAMBERT EH, ROOKE ED: Myasthenic state and lung cancer. In: The remote effects of cancer on the nervous system. Lord Brain, Norris FH (eds). Grune & Stratton, New York (1965):67-80.
6. O'NEILL JH, MURRAY NM, NEWSOM-DAVIS J: The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain (1988) 111:577-596. •• A hallmark paper giving a detailed description of 50 patients with LEMS.
7. SOMNIER FE, KEIDING N, PAULSON OB: Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch. Neurol. (1991) 48:733-739.
8. WIRTZ PW, VAN DIJK JG, VAN DOORN PA et al.: The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands. Neurology (2004) 63(2):397-398. (Pubitemid 38971159)
9. PHILLIPS LH II, TORNER JC: Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology (1996) 47(5):1233-1238. (Pubitemid 26374892)
10. ROBERTSON NP, DEANS J, COMPSTON DA: Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J. Neurol. Neurosurg. Psychiatry (1998) 65(4):492-496. (Pubitemid 28438878)
11. WIRTZ PW, NIJNUIS MG, SOTODEH M et al.: Dutch Myasthenia Study Group. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J. Neurol. (2003) 250:698-701.
12. LANG B, NEWSOM-DAVIS J, WRAY D, VINCENT A, MURRAY N: Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet (1981) 2(8240):224-226. (Pubitemid 11095446)
13. LINDSTROM JM, SEYBOLD ME, LENNON VA, WHITTINGHAM S, DUANE DD: Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology (1976) 26(11):1054-1059.
14. JANER M, COWLAND A, PICARD J et al.: A susceptibility region for myasthenia gravis extending into the HLA- class I sector telomeric to HLA-C. Hum. Immunol. (1999) 60:909-917.
15. WIRTZ PW, WILLCOX N, VAN DER SLIK AR et al.: HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J. Neuroimmunol. (2005) 159(1-2):230-237. • Describing a clear diference in HLA association between LEMS with or without tumour. Only non-tumour LEMS has a strong HLA-B8DR3 association. (Pubitemid 40126197)
16. WIRTZ PW, SOTODEH M, NIJNUIS M et al.: Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry. (2002) 73(6):766-768.
17. WIRTZ PW, SMALLEGANGE TM, WINTZEN AR, VERSCHUUREN JJ: Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin. Neurol. Neurosurg. (2002) 104(4):359-363.
18. MADDISON P, NEWSOM-DAVIS J: Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst. Rev. (2005) 2:CD003279.
19. MCEVOY KM, WINDEBANK AJ, DAUBE JR, LOW PA: 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N. Engl. J. Med. (1989) 321(23):1567-1571. •• One of the three reported randomised trials in LEMS. Provess the beneficial effect of 3,4-DAP in the treatment of LEMS.
20. BAIN PG, MOTOMURA M, NEWSOM-DAVIS J et al.: Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology (1996) 47(3):678-683. •• One of the three reported randomised trials in LEMS. (Pubitemid 26307297)
21. SANDERS DB, MASSEY JM, SANDERS LL, EDWARDS LJ: A randomised trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology (2000) 54(3):603-607. •• One of the three reported randomised trials in LEMS. (Pubitemid 30082925)
22. MINOT AN, DODD K, RIVEN SS: Use of guanidine hydrochloride in treatment of myasthenia gravis. JAMA (1939) 113:553-559.
23. LAMBERT EH: Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann. N. Y. Acad. Sci. (1966) 135:367-384.
24. MOLGÓ J, MALLART A: The mode of action of guanidine on mouse motor nerve terminals. Neurosc. Lett. (1988) 89:161-164.
25. LUNDH H, NILSSON O, ROSÉN I: Current therapy of the Lambert-Eaton myasthenic syndrome. Prog. Brain Res. (1990) 84:163-170.
26. KAMENSKAYA MA, ELMQVIST D, THESLEFF S: Guanidine and neuromuscular transmission. II. Effect on transmitter release in response to repetitive nerve stimulation. Arch. Neurol. (1975) 32(8):510-518.
27. OH SJ, KIM DS, HEAD TC, CLAUSEEN GC: Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve (1997) 20:1146-1152. (Pubitemid 27352098)
28. TIM RW, MASSEY JM, SANDERS DB: Lambert-Eaton myasthenic syndrome: Electrodiagnostic findings and response to treatment. Neurology (2000) 54:2176-2178. • Describes electrodiagnostic findings and the effect of several treatment modalities in a large series of LEMS patients. (Pubitemid 30397227)
29. NORRIS FH, CALANCHINI PR, FALLAT RJ, PANCHARI S, JEWETT B: The administration of guanidine in amyotrophic lateral sclerosis. Neurology (1974) 24:721-728.
30. OH SJ, KIM KW: Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement. Neurology (1973) 23:1084-1090.
31. CHERINGTON M: Guanidine and germine in Eaton-Lambert syndrome. Neurology (1976) 26:944-946.
32. BLUMHARDT LD, JOEKES AM, MARSHALL J, PHILALITHIS PE: Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome. BMJ (1977) 1:946-947. (Pubitemid 8090166)
33. SILBERT PL, HANKEY GJ, BARR AL: Successful alternate day guanidine therapy following guanidine-induced neutropenia in the Lambert-Eaton myasthenic syndrome. Muscle Nerve (1990) 13(4):360-361. (Pubitemid 20127636)
34. NAKANO KK, TYLER HR: Cardiovascular complications of guanidine therapy in the myasthenic syndrome. Neurology (1970) 20(4):408.
35. DAU PC, DENYS EH: Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert myasthenic syndrome. Ann. Neurol. (1982) 11:570-575.
36. LEMEIGNAN M, MILLART H, LAMIABLE D, MOLGO J, LECHAT P: Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res. (1984) 304(1):166-169. (Pubitemid 14123328)
37. MOLGÓ J, LUNDH H, THESLEFF S: Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur. J. Pharmacol. (1980) 61(1):25-34.
38. AGOSTON S, VAN WEERDEN T, WESTRA P, BROEKERT A: Effects of 4-aminopyridine in Eaton Lambert Syndrome. Br. J. Anaesth. (1978) 50(4):383-385.
39. LUNDH H, NILSSON O, ROSÉN I: 4-Aminopyridine - a new drug tested in the treatment of Eaton-Lambert syndrome. J. Neurol. Neurosurg. Psychiatry (1977) 40:1109-1112.
40. SANDERS DB, KIM YI, HOWARD JF JR, GOETSCH CA: Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine. J. Neurol. Neurosurg. Psychiatry. (1980) 43(11):978-985.
41. MURRAY NMF, NEWSOM-DAVIS J: Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology (1981) 31:265-271. (Pubitemid 11146987)
42. KIM YI, GOLDNER MM, SANDERS DB: Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. Muscle Nerve (1980) 3(2):112-119. (Pubitemid 10134617)
43. LECHAT P, DEYSSON G, LEMEIGNAN M, ADOLPHE M: Comparison of acute toxicity of some aminopyridines in vivo (mice) and in vitro (tissue culture) [Toxicité aigue composeé de quelques aminopyridines in vivo (souris) et in vitro (cultures cellulaires)]. Annales de Pharmacologie (1968) 26(5):345-349.
44. SMEETS JW, KUNST MW: Severe intoxication with 4-aminopyridine in a bodybuilder. Ned. Tijdschr. Geneeskd. (1995) 139:51.
45. SPYKER DA, LYNCH C, SHABANOWITZ J, SINN JA: Poisoning with 4-aminopyridine: report of three cases. Clin. Toxicol. (1980) 16(4):487-497.
46. SOLARI A, UITDEHAAG B, GIULIANI G, PUCCI E, TAUS C: Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst. Rev. (2003) 2:CD001330.
47. BEVER CT JR, YOUNG D, ANDERSON PA et al.: The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology (1994) 44(6):1054-1059. (Pubitemid 24188176)
48. UGES DRA, BUIRS B, SANGSTER B: Treatment of 4-aminopyridine-poisining after oral overdose; a proposal. Pharm. Acta Helv. (1984) 59:172-176.
49. LUNDH H, NILSSON O, ROSÉN I: Novel drug of choice in Eaton-Lambert syndrome. J. Neurol. Neurosurg. Psychiatry (1983) 46:684-685.
50. LUNDH H, NILSSON O, ROSÉN I, JOHANSSON S: Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol. Scand. (1993) 88(2):136-140. • Nice description of the effect of 3,4-DAP in a large series of patients with LEMS.
51. BOERMA CE, ROMMES JH, VAN LEEUWEN RB, BAKKER J: Cardiac arrest following an iatrogenic 3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J. Toxicol. Clin. Toxicol. (1995) 33(3):249-251.
52. BEVER CT JR, ANDERSON PA, LESLIE J et al.: Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology (1996) 47(6):1457-1462. (Pubitemid 26422536)
53. MILLER RD, DENNISSEN PA, VAN DER POL F, AGOSTON S, BOOIJ LH, CRUL JF: Potentiation of neostigmine and pyridostigmine by 4-aminopyridine in the rat. J. Pharm. Pharmacol. (1978) 30(11):699-702.
54. LUNDH H, NILSSON O, ROSÉN I: Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology (1984) 34(10):1324-1330.
55. WALKER MB: Treatment of myasthenia gravis with physostigmine. Lancet (1934) 1:1200-1201.
56. WIRTZ PW, VAN GERVEN JMA, VAN DIJK JG et al.: The effects of 3, 4-diaminopyridine (DAP) and pyridostigimine (PS) on muscle function in the Lambert-Eaton myasthenic syndrome (LEMS): a double-blind placebo controlled cross-over study - abstract. Neuromuscul. Dis. (2002) 7(8):760.
57. DALAKAS MC: Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA (2004) 291:2367-2375. (Pubitemid 38656304)
58. BUCHWALD B, AHANGARI R, WEISHAUPT A, TOYKA KV: Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle Nerve (2005) 31(4):487-494. (Pubitemid 40393094)
59. VROOM FQ, ENGEL WK: Nonneoplastic steroid responsive Lambert-Eaton myasthenic syndrome. Neurology (1969) 19:281.
60. KIMURA I, AYYAR DR: The Eaton-Lambert myasthenic syndrome and long-term treatment with prednisolone. Tohoku J. Exp. Med. (1984) 143:405-408.
61. STREIB EW, ROTHNER AD: Eaton-Lambert myasthenic syndrome: long-term treatment of three patients with prednisone. Ann. Neurol. (1981) 10(5):448-453.
62. NEWSOM-DAVIS J, MURRAY NMF: Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology (1984) 34:480-485. • Early study describing the effect of immunomodulating and immunosuppressive treatment in LEMS. (Pubitemid 14127311)
63. TIM RW, MASSEY JM, SANDERS DB: Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann. N. Y. Acad. Sci. (1998) 841:823-826.
64. HALL ED: Glucocorticoid enhancement of guanidine neuromuscular facilitation. Exp. Neurol. (1980) 68(3):581-588.
65. SANDERS DB: Lambert-eaton myasthenic syndrome: diagnosis and treatment. Ann. N. Y. Acad. Sci. (2003) 998:500-508.
66. HENZE T: Myasthenia gravis and myasthenic syndromes. Part II. Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes and botulism. Drugs Today (1997) 33:543-553.
67. MASCAUX C, PAESMANS M, BERGHMANS T et al.: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer (2000) 30(1):23-36.
68. SUNDSTROM S, BREMNES RM, KAASA S et al.: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J. Clin. Oncol. (2002) 20(24):4665-4672.
69. SUNDSTROM S, BREMNES RM, KAASA S, AASEBO U, Aamdal S; Norwegian Lung Cancer Study Group: Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer (2005) 48(2):251-261.
70. THATCHER N, FAIVRE-FINN C, LORIGAN P: Lung cancer: management of small-cell lung cancer. Ann. Oncol. (2005) 16(Suppl. 2):ii235-ii239.
71. PAESMANS M, SCULIER JP, LECOMTE J et al.: Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer (2000) 89(3):523-533. (Pubitemid 30640099)
72. CHALK CH, MURRAY NM, NEWSOM-DAVIS J, O'NEILL JH, SPIRO SG: Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology (1990) 40(10):1552-1556. (Pubitemid 20351348)
73. MADDISON P, NEWSOM-DAVIS J, MILLS KR, SOUHAMI RL: Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet (1999) 353(9147):117-118. (Pubitemid 29088084)
74. JENKYN LR, BROOKS PL, FORCIER RJ, MAURER LH, OCHOA J: Remission of the Lambert-Eaton syndrome and small cell anaplastic carcinoma of the lung induced by chemotherapy and radiotherapy. Cancer (1980) 46(5):1123-1127. (Pubitemid 10043478)
75. MEDINA JE, MORAN M, GOEPFERT H: Oat cell carcinoma of the larynx and Eaton-Lambert syndrome. Arch. Otolaryngol. (1984) 110:123.
76. CLAMON GH, EVANS WK, SHEPHERD FA, HUMPHREY JG: Myasthenic syndrome and small cell cancer of the lung. Variable response to antineoplastic therapy. Arch. Intern. Med. (1984) 144(5):999-1000.
77. GEDDES DM: The natural history of lung cancer: a review based on rates of tumour growth. Br. J. Dis. Chest (1979) 73:1-17.
78. LINKE R, SCHROEDER M, HELMBERGER T, VOLTZ R: Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology (2004) 63(2):282-286. (Pubitemid 38971127)
79. MULSHINE JL, SULLIVAN DC: Lung cancer screening. N. Engl. J. Med. (2005) 352:2714-2720
80. WIRTZ PW, WINTZEN AR, VERSCHUUREN JJ: Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer. Muscle Nerve (2005) 32(2):226-229. (Pubitemid 41061497)
81. RICHMAN DP, AGIUS MA: Treatment of autoimmune myasthenia gravis. Neurology (2003) 61(12):1652-1661. (Pubitemid 38020807)
82. ROWIN J, MERIGGIOLI MN, TUZUN E, LEURGANS S, CHRISTADOSS P: Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology (2004) 63(12):2390-2392. (Pubitemid 40024358)
83. KENNEDY WR, JIMENEZ-PABON E: The myasthenic syndrome associated with small cell carcinoma of the lung (Eaton-Lambert syndrome). Neurology (1968) 18(8):757-766.
84. OH SJ: The Eaton-Lambert syndrome. Report of a case. Arch. Neurol. (1972) 27(1):91-94.
85. HENRIKSSON KG, NILSSON O, ROSEN I, SCHILER HH: Clinical, neurophysiological and morphological findings in Eaton-Lambert syndrome. Acta Neurol. Scand. (1977) 56:117-140.
86. STREIB EW: Reversible hepatic dysfunction owing to guanidine treatment. Arch. Neurol. (1979) 36(6):386.
87. JABLECKI C: Lambert-Eaton myasthenic syndrome. Muscle Nerve (1984) 7:250-257. (Pubitemid 14150157)
88. TAKAMORI M: Caffeine, calcium, and Eaton-Lambert syndrome. Arch. Neurol. (1972) 27(4):285-291.
89. SADEH M, RIVER Y, ARGOV Z: Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome before and after 3,4-diaminopyridine. Muscle Nerve (1997) 20(6):735-739. (Pubitemid 27197727)
90. BIRD SJ: Clinical and electrophysiological improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology (1992) 42(7):1422-1423.
91. TAKANO H, TANAKA M, KOIKE R, NAGAI H, ARAKAWA M, TSUJI S: Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve (1994) 17(9):1073-1075. (Pubitemid 24271457)
92. MUCHNIK S, LOSAVIO AS, VIDAL A, CURA L, MAZIA C: Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve (1997) 20(6):674-678. (Pubitemid 27197719)
93. OH SJ: SFEMG improvement with remission in the cancer-associated Lambert-Eaton myasthenic syndrome. Muscle Nerve (1989) 12(10):844-848. (Pubitemid 19250889)